Fevaxyn Pentofel

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

inactivated feline rhinotracheitis virus, inactivated feline calicivirus, inactivated feline Chlamydophila felis, inactivated feline leukaemia virus, inactivated feline panleukopenia virus

Available from:

Zoetis Belgium SA 

ATC code:

QI06AL01

INN (International Name):

inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis

Therapeutic group:

mačke

Therapeutic area:

Immunologicals

Therapeutic indications:

Za aktivna imunizacija zdravih mačaka devet tjedana i stariji protiv панлейкопении i virus mačje leukemije i protiv respiratornih bolesti uzrokovane virusom ринотрахеита mačke, mačka калицивирус i klamidija feliz.

Product summary:

Revision: 20

Authorization status:

odobren

Authorization date:

1997-02-05

Patient Information leaflet

                                13
B. UPUTA O VMP
14
UPUTA O VMP
FEVAXYN PENTOFEL, SUSPENZIJA
ZA INJEKCIJE, ZA MAČKE
1.
IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije u promet:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIJA
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Fevaxyn Pentofel, suspenzija za injekciju, za mačke
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Po dozi od 1 ml (štrcaljka s pojedinačnom dozom):
DJELATNE TVARI
RELATIVNA POTENTNOST (R.P.)
Inaktivirani virus panleukopenije mačaka (soj CU4)
Inaktivirani mačji kalicivirus (soj 255)
Inaktivirani virus mačjeg rinotraheitisa (soj 605)
Inaktivirani
_Chlamydophila felis _
(soj Cello)
_ _
Inaktivirani virus mačje leukemije (soj 61E)
≥ 8,50
≥ 1,26
≥ 1,39
≥ 1,69
≥ 1,45
ADJUVANSI
Etilen/Anhidrid maleinske kiseline (EMA-31)
Neokril
Emulzigen SA
1% (v/v)
3% (v/v)
5% (v/v)
4.
INDIKACIJE
Za aktivnu imunizaciju zdravih mačaka starih devet tjedana ili
starijih protiv virusa panleukopenije
mačaka i mačje leukemije, te respiratornih bolesti uzrokovanih
virusom mačjeg rinotraheitisa, mačjim
kalicivirusom i
_Chlamydophilom felis._
5.
KONTRAINDIKACIJE
Nema.
6.
NUSPOJAVE
Mačke nakon cijepljenja mogu imati reakcije koje uključuju prolaznu
vrućicu, povraćanje, anoreksiju
i/ili depresiju, koje obično nestaju unutar 24 sata.
Na mjestu ubrizgavanja mogu se pojaviti i lokalne reakcije poput
oteklina, boli, svrbeža ili gubitka
dlake.
15
Anafilaktoidne reakcije s edemom, svrbežom, respiracijskim i srčanim
smetnjama, teškim
gastrointestinalnim simptomima (uključujući hematemezu i
hemoragijski proljev) ili šokom pojavili su
se u vrlo rijetkim slučajevima u prvih nekoliko sati nakon
cijepljenja.
Učestalost nuspojava je određena sukladno sljedećim pravilima:
- vrlo česte (više od 1 na 10 tretiranih životinja pokazuju
nuspojavu(e))
- 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Fevaxyn Pentofel, suspenzija za injekcije, za mačke
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Po dozi od 1 ml (štrcaljka s pojedinačnom dozom):
DJELATNE TVARI
RELATIVNA POTENTNOST (R.P.)
Inaktivirani virus panleukopenije mačaka (soj CU4)
Inaktivirani mačji kalicivirus (soj 255)
Inaktivirani virus mačjeg rinotraheitisa (soj 605)
Inaktivirana
_Chlamydophila felis _
(soj Cello)
_ _
Inaktivirani virus mačje leukemije (soj 61E)
≥ 8,50
≥ 1,26
≥ 1,39
≥ 1,69
≥ 1,45
ADJUVANSI
Etilen/Anhidrid maleinske kiseline (EMA-31)
Neokril
Emulzigen SA
1% (v/v)
3% (v/v)
5% (v/v)
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Suspenzija za injekciju.
Izgled cjepiva je u obliku mliječne ružičaste tekućine bez ikakvih
krutih čestica.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Mačke.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za aktivnu imunizaciju zdravih mačaka starih devet tjedana ili
starijih protiv virusa panleukopenije
mačaka i mačje leukemije, te respiratornih bolesti uzrokovanih
virusom mačjeg rinotraheitisa, mačjim
kalicivirusom i
_Chlamydophilom felis._
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Cjepivo ne utječe na tijek infekcije virusom mačje leukemije kod
mačaka koje su već zaražene tim
virusom u vrijeme cijepljenja, što implicira da će takve mačke
izlučivati virus mačje leukemije bez
obzira na cijepljenje. Zbog toga će te životinje predstavljati
opasnost za one mačke u svojem okolišu
koje su podložne zarazi. Prije cijepljenja preporučuje se testirati
mačke kod kojih je prisutna veća
vjerojatnost izloženosti virusu mačje leukemije na antigen tog
virusa. Životinje s negativnim nalazom
mogu se cijepiti, a životinje s pozitivnim nalazom treba izolirati od
ostalih mačaka i ponovo testirati u
roku od mjesec-dva. Mačke koje su pozitivne na drugom testiranju
trebalo bi smatrati trajno
3
zaraženima virusom 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-03-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-03-2022
Public Assessment Report Public Assessment Report Bulgarian 07-06-2013
Patient Information leaflet Patient Information leaflet Spanish 01-03-2022
Public Assessment Report Public Assessment Report Spanish 07-06-2013
Patient Information leaflet Patient Information leaflet Czech 01-03-2022
Public Assessment Report Public Assessment Report Czech 07-06-2013
Patient Information leaflet Patient Information leaflet Danish 01-03-2022
Public Assessment Report Public Assessment Report Danish 07-06-2013
Patient Information leaflet Patient Information leaflet German 01-03-2022
Public Assessment Report Public Assessment Report German 07-06-2013
Patient Information leaflet Patient Information leaflet Estonian 01-03-2022
Public Assessment Report Public Assessment Report Estonian 07-06-2013
Patient Information leaflet Patient Information leaflet Greek 01-03-2022
Public Assessment Report Public Assessment Report Greek 07-06-2013
Patient Information leaflet Patient Information leaflet English 01-03-2022
Public Assessment Report Public Assessment Report English 07-06-2013
Patient Information leaflet Patient Information leaflet French 01-03-2022
Public Assessment Report Public Assessment Report French 07-06-2013
Patient Information leaflet Patient Information leaflet Italian 01-03-2022
Public Assessment Report Public Assessment Report Italian 07-06-2013
Patient Information leaflet Patient Information leaflet Latvian 01-03-2022
Public Assessment Report Public Assessment Report Latvian 07-06-2013
Patient Information leaflet Patient Information leaflet Lithuanian 01-03-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-03-2022
Public Assessment Report Public Assessment Report Lithuanian 07-06-2013
Patient Information leaflet Patient Information leaflet Hungarian 01-03-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 01-03-2022
Public Assessment Report Public Assessment Report Hungarian 07-06-2013
Patient Information leaflet Patient Information leaflet Maltese 01-03-2022
Public Assessment Report Public Assessment Report Maltese 07-06-2013
Patient Information leaflet Patient Information leaflet Dutch 01-03-2022
Public Assessment Report Public Assessment Report Dutch 07-06-2013
Patient Information leaflet Patient Information leaflet Polish 01-03-2022
Public Assessment Report Public Assessment Report Polish 07-06-2013
Patient Information leaflet Patient Information leaflet Portuguese 01-03-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 01-03-2022
Public Assessment Report Public Assessment Report Portuguese 07-06-2013
Patient Information leaflet Patient Information leaflet Romanian 01-03-2022
Public Assessment Report Public Assessment Report Romanian 07-06-2013
Patient Information leaflet Patient Information leaflet Slovak 01-03-2022
Public Assessment Report Public Assessment Report Slovak 07-06-2013
Patient Information leaflet Patient Information leaflet Slovenian 01-03-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 01-03-2022
Public Assessment Report Public Assessment Report Slovenian 07-06-2013
Patient Information leaflet Patient Information leaflet Finnish 01-03-2022
Public Assessment Report Public Assessment Report Finnish 07-06-2013
Patient Information leaflet Patient Information leaflet Swedish 01-03-2022
Public Assessment Report Public Assessment Report Swedish 07-06-2013
Patient Information leaflet Patient Information leaflet Norwegian 01-03-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 01-03-2022
Patient Information leaflet Patient Information leaflet Icelandic 01-03-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 01-03-2022